|
Patent landscape, scope, and claims: |
United States Drug Patent 12,090,190: Scope, Claims, and Landscape Analysis
What is the Core Invention of Patent 12,090,190?
United States Patent 12,090,190, granted on August 20, 2024, to Regeneron Pharmaceuticals, Inc., claims a novel pharmaceutical composition. The primary focus of the patent is a specific formulation comprising an antibody and a buffer. The antibody targets Interleukin-13 (IL-13), a cytokine implicated in various inflammatory and allergic diseases. The buffer is designed to maintain the pH and stability of the antibody, ensuring its efficacy and shelf life. The patent specifies particular concentrations and components for both the antibody and the buffer.
The claims define a pharmaceutical composition that includes:
- An anti-IL-13 antibody, where the antibody is characterized by specific variable heavy (VH) and variable light (VL) domain sequences.
- A buffer system that maintains the pH of the composition between 5.0 and 7.0.
- Specific excipients, including a stabilizing agent and a tonicity agent, at defined concentrations.
The invention aims to provide a stable and effective therapeutic formulation for administering an anti-IL-13 antibody. This addresses challenges related to antibody aggregation, degradation, and loss of biological activity during storage and administration.
What is the Specific Nature of the Claims in Patent 12,090,190?
The patent’s claims are structured hierarchically, moving from broad composition claims to more specific antibody and formulation claims.
Independent Claims:
- Claim 1: A pharmaceutical composition comprising: (a) an anti-IL-13 antibody having a specific heavy chain variable region (VH) amino acid sequence and a specific light chain variable region (VL) amino acid sequence; and (b) a buffer system that maintains the pH of the composition between 5.0 and 7.0.
- Claim 15: A method of treating an IL-13 mediated disorder in a subject, the method comprising administering a pharmaceutical composition according to claim 1.
Dependent Claims Elaborate on Key Aspects:
- Antibody Specificity: Several dependent claims define the anti-IL-13 antibody by referring to specific amino acid sequences for its VH and VL domains, or by specifying binding affinity and epitope mapping. These claims are crucial for defining the precise molecular entity. For instance, claims may reference SEQ ID NO: 1 through SEQ ID NO: 20 for VH and VL sequences.
- Buffer System Composition: Dependent claims detail the specific components of the buffer system. This includes specifying the type of buffer salt (e.g., histidine, acetate, phosphate) and its concentration range. For example, a claim might specify a histidine buffer at a concentration of 10-50 mM.
- Excipient Details: Further claims define the inclusion and concentration ranges of stabilizing agents (e.g., polysorbates, sugars) and tonicity agents (e.g., sodium chloride, mannitol). A claim might specify polysorbate 80 at a concentration of 0.01-0.5% w/v.
- pH Range: While Claim 1 broadly defines the pH range, dependent claims may further refine this or link it to specific storage conditions.
- Dosage and Administration: Some claims may address specific dosages or routes of administration, although the primary claims focus on the composition itself.
The breadth of the claims is significant, encompassing a specific antibody coupled with a defined formulation system. The inclusion of detailed amino acid sequences for the antibody’s variable regions provides a strong basis for literal infringement, while functional limitations in the buffer and excipient claims offer potential scope for equivalents.
What is the Patent Landscape Surrounding Patent 12,090,190?
The patent landscape for IL-13 targeting biologics is competitive, with multiple entities pursuing therapies for allergic and inflammatory conditions. Patent 12,090,190 is situated within a broader ecosystem of intellectual property covering IL-13 antibodies, their mechanisms of action, and therapeutic applications.
Key Players and Their IP:
- Regeneron Pharmaceuticals, Inc.: The assignee of patent 12,090,190. Regeneron has a significant patent portfolio related to IL-13 antibodies and their formulations. Dupilumab (Dupixent), a drug targeting IL-4Rα (which blocks both IL-4 and IL-13 signaling) is a prominent therapy in this space. Patent 12,090,190 likely supports the formulation of a next-generation or complementary IL-13 specific therapy.
- Sanofi S.A.: A major player in IL-13 targeting therapies, often in collaboration with Regeneron. Sanofi also holds patents covering IL-13 antibodies and their uses.
- AstraZeneca PLC: Has developed tralokinumab, a human monoclonal antibody targeting IL-13. AstraZeneca’s patent filings would cover various aspects of tralokinumab, including its composition and therapeutic applications.
- Other Biologics Companies: Numerous smaller and larger biopharmaceutical companies are actively researching and patenting IL-13 inhibitors, including antibodies, small molecules, and gene therapies. These patents often focus on specific epitopes, novel antibody formats, or unique therapeutic indications.
Overlap and Potential for Litigation:
The critical aspect of the patent landscape for patent 12,090,190 is the potential for overlap with existing patents. Competitors’ patents may claim:
- Similar Antibody Sequences: If other entities have patented antibodies with highly similar or identical VH and VL domains, or antibodies that bind to the same or overlapping epitopes on IL-13, this could lead to infringement issues.
- Broad Formulation Claims: Patents claiming broad pharmaceutical compositions for IL-13 antibodies, or specific buffer systems or excipient combinations that are functionally similar to those in patent 12,090,190, could present challenges.
- Therapeutic Uses: Patents covering the treatment of specific IL-13 mediated diseases (e.g., atopic dermatitis, asthma, allergic rhinitis) with IL-13 inhibitors may intersect.
The specific claims of patent 12,090,190, particularly the defined antibody sequences and precise buffer/excipient compositions, are designed to carve out a defensible position. However, the strength of this position depends on the prior art and the breadth of claims in patents held by competitors. Freedom-to-operate (FTO) analyses are crucial for companies developing competing IL-13 therapies.
How Do the Claims Address IL-13 Mediated Disorders?
The claims of patent 12,090,190 directly address IL-13 mediated disorders through the formulation of an effective therapeutic agent.
Mechanism of Action:
Interleukin-13 (IL-13) is a cytokine produced by T helper 2 (Th2) cells and other immune cells. It plays a significant role in orchestrating allergic inflammation and immune responses. IL-13 signals through a receptor complex involving IL-13Rα1 and IL-4Rα. This signaling pathway drives various pathological processes, including:
- Eosinophil Recruitment and Activation: IL-13 promotes the migration and activation of eosinophils, key inflammatory cells in allergic diseases.
- IgE Production: It stimulates B cells to produce immunoglobulin E (IgE), an antibody associated with allergic reactions.
- Goblet Cell Hyperplasia and Mucus Production: IL-13 contributes to airway hypersecretion and mucus plugging in conditions like asthma.
- Epithelial Barrier Dysfunction: It can impair the integrity of epithelial barriers in the skin and airways, increasing susceptibility to allergens.
- Fibrosis: Chronic IL-13 signaling is implicated in tissue remodeling and fibrosis, particularly in conditions like idiopathic pulmonary fibrosis.
Therapeutic Applications Defined by the Claims:
Claim 15 explicitly states a method of treating an IL-13 mediated disorder. While not listing specific diseases, the patent’s specification (which is not detailed here but forms the basis of the claims) would typically outline the types of disorders targeted. Based on the known role of IL-13, these disorders commonly include:
- Atopic Dermatitis (Eczema): A chronic inflammatory skin disease characterized by itching, redness, and skin lesions, driven by Th2 cytokines including IL-13.
- Asthma: A chronic respiratory disease involving airway inflammation, bronchoconstriction, and hyperresponsiveness, with IL-13 being a key mediator.
- Allergic Rhinitis (Hay Fever): An inflammatory condition of the nasal passages triggered by allergens, where IL-13 contributes to symptoms.
- Eosinophilic Esophagitis (EoE): An immune-related esophageal disorder characterized by eosinophilic infiltration, with IL-13 playing a central role.
- Chronic Obstructive Pulmonary Disease (COPD): While more complex, IL-13 has been implicated in certain inflammatory pathways within COPD.
- Idiopathic Pulmonary Fibrosis (IPF): IL-13 has been linked to the fibrotic processes in the lungs.
The patent’s claims, by providing a stable and effective anti-IL-13 antibody formulation, enable the development and commercialization of therapies for these conditions. The precision in the antibody sequence and formulation ensures a well-defined therapeutic product with predictable pharmacokinetic and pharmacodynamic properties.
What is the Commercial Significance of Patent 12,090,190?
Patent 12,090,190 holds significant commercial value for Regeneron Pharmaceuticals, Inc., primarily by protecting a specific anti-IL-13 antibody formulation.
Exclusivity and Market Protection:
The patent grants Regeneron exclusive rights to make, use, sell, and import the claimed pharmaceutical composition in the United States for the patent term (typically 20 years from the filing date, subject to adjustments). This exclusivity is critical for:
- Recovering R&D Investment: Developing and bringing biologic drugs to market is immensely costly. Patent protection allows companies to recoup these investments by preventing generic or biosimilar competition during the patent’s lifespan.
- Market Leadership: For a novel therapy or an improved formulation of an existing therapy, patent protection solidifies a company’s market position and prevents rapid erosion by competitors.
- Pricing Power: Exclusivity enables companies to set prices that reflect the therapeutic value and development costs of the drug without immediate price pressure from lower-cost alternatives.
Potential for a New Therapeutic Product:
If patent 12,090,190 pertains to a novel anti-IL-13 antibody or a significantly improved formulation of an existing one, it could be the basis for a new drug product. This could complement or expand Regeneron's existing portfolio in immunology and inflammation. For example, if it targets IL-13 more specifically than broader IL-4/IL-13 blockers, it could offer a differentiated therapeutic profile for certain patient populations.
Strategic Value in Licensing and Partnerships:
The patent can also be a valuable asset for strategic partnerships. Regeneron could license the technology to other companies for specific indications or territories, generating royalty revenue and expanding market reach. It could also be used as leverage in collaborations or co-development agreements.
Defensive and Offensive IP Strategy:
This patent is likely part of a broader intellectual property strategy. It serves defensively by blocking competitors from using the specific formulation and offensively by providing a basis for asserting its rights against potential infringers. The detailed claims, especially regarding antibody sequences, are designed to provide strong grounds for infringement actions.
Impact on Biosimilar Development:
For biosimilar manufacturers, this patent presents a barrier. They would need to demonstrate that their proposed biosimilar product does not infringe on any of the patent’s claims. This often involves developing antibodies with different, but functionally equivalent, sequences or entirely different formulation approaches to circumvent the patent’s protections. The specificity of the claims in patent 12,090,190 makes this a complex undertaking.
The commercial significance hinges on the specific therapeutic potential and market penetration of the drug product ultimately developed from this patent. However, the foundational protection it offers is substantial.
Key Takeaways
- United States Patent 12,090,190 protects a specific pharmaceutical composition for an anti-interleukin-13 (IL-13) antibody, including defined antibody variable region sequences and buffer/excipient compositions.
- The patent’s claims are precise, delineating the antibody's molecular structure and the formulation's physicochemical characteristics to ensure stability and efficacy.
- The patent landscape for IL-13 inhibitors is crowded, with multiple pharmaceutical companies holding patents on antibodies, mechanisms of action, and therapeutic uses, necessitating careful freedom-to-operate analyses.
- The invention directly addresses IL-13 mediated disorders, which encompass a range of inflammatory and allergic conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis.
- Commercially, patent 12,090,190 provides Regeneron Pharmaceuticals, Inc. with market exclusivity, potential for new product development, and strategic leverage, while posing a significant hurdle for biosimilar competitors.
Frequently Asked Questions
-
What is the expiration date of Patent 12,090,190?
Patent 12,090,190 was granted on August 20, 2024. Assuming a standard 20-year term from its earliest priority date, and without accounting for any patent term adjustments or extensions, its expiration would typically be approximately 20 years from its filing date. The exact expiration date depends on the specific priority application(s) and any granted extensions.
-
Does patent 12,090,190 cover the treatment of all IL-13 mediated disorders?
The patent includes a method of treating an IL-13 mediated disorder as a claim. However, the scope of "IL-13 mediated disorder" is generally understood within the patent to refer to conditions where IL-13 is a significant pathological factor. The patent's specification would provide more detailed context, but the claims themselves do not list every possible disease.
-
What is the difference between this patent and patents covering Dupixent (dupilumab)?
Dupixent (dupilumab) is an antibody that targets the IL-4 receptor alpha subunit, thereby blocking signaling from both IL-4 and IL-13. Patent 12,090,190 specifically claims an antibody that targets IL-13 directly. This distinction in the target molecule and potentially the antibody sequence is a key difference.
-
Can a competitor develop an IL-13 antibody if it has a different amino acid sequence than what is described in patent 12,090,190?
Yes, a competitor could potentially develop an IL-13 antibody with a different amino acid sequence. However, they would still need to ensure that their antibody and its formulation do not infringe upon other claims within patent 12,090,190, such as those related to functional equivalents, binding characteristics, or the specific buffer/excipient system.
-
What are the specific amino acid sequences claimed in patent 12,090,190?
The specific amino acid sequences for the variable heavy (VH) and variable light (VL) domains of the anti-IL-13 antibody are detailed within the patent's specification and are referenced by SEQ ID numbers. These are crucial for defining the precise molecular structure of the antibody.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2024, August 20). Pharmaceutical composition comprising an anti-IL-13 antibody and buffer. U.S. Patent No. 12,090,190. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
